{"disease":{"id":"transarterial-chemoembolization","name":"transarterial chemoembolization"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06008548","title":"A New Conception About Individualized Treatment Allocation for HCC","phase":"","overall_status":"COMPLETED","enrollment_count":4991,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT06788353","title":"Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07417397","title":"Adjuvant TACE in HCC With High-risk Recurrence Factors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":442,"lead_sponsor_name":"Guangxi Medical University","has_results":false},{"nct_id":"NCT07449065","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05390112","title":"Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization","phase":"","overall_status":"UNKNOWN","enrollment_count":167,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT04103398","title":"TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04997850","title":"The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Xinrui Zhu，MD","has_results":false},{"nct_id":"NCT07315022","title":"Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06485466","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":101,"lead_sponsor_name":"Guohui Xu","has_results":false},{"nct_id":"NCT03277716","title":"Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fan Weijun","has_results":false},{"nct_id":"NCT05416073","title":"Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT04597970","title":"TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07178093","title":"Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Taichung Tzu Chi Hospital","has_results":false},{"nct_id":"NCT04531228","title":"TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Yunfei Yuan","has_results":false},{"nct_id":"NCT05025592","title":"cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07281664","title":"Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04834674","title":"DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT07198230","title":"Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Ting YANG","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}